Abstract
Neutrophil elastase, a serine proteinase from the chymotrypsin family, has been the object of comprehensive experimental and theoretical studies to develop efficient human neutrophil elastase inhibitors. The serine protease has been linked to the pathology of a variety of inflammatory diseases, making it an attractive target for the development of anti-inflammatory compounds.
In this work, we have built a common binding model of the 2-pyridin-3-yl-benzo[d][1,3]oxazin-4-one derivatives into the human neutrophil elastase binding site. This was accomplished through a comparative conformational analysis (using OMEGA, HYPERCHEM, and MOPAC software) of 2-pyridin-3-yl-benzo[d][1,3]oxazin-4-one inhibitors followed by rigid and flexible molecular docking (by the FRED and GLIDE programs) into the target protein. We conclude that OMEGA software generates the most representative conformers to model the protein-ligand interactions.Keywords: Conformational analysis, Benzoxazinone derivative, Biologically active conformation, Human neutrophil elastase inhibitor, Molecular docking, serine proteinase, chymotrypsin family, anti-inflammatory compounds, 2-pyridin-3-yl-benzo[d][1, 3]oxazin-4-one derivatives, MOPAC software
Current Pharmaceutical Design
Title:Modeling of 2-Pyridin-3-yl-Benzo[d][1,3]Oxazin-4-one Derivatives by Several Conformational Searching Tools and Molecular Docking
Volume: 19 Issue: 12
Author(s): Mohammad Goodarzi, Alina Bora, Ana Borota, Simona Funar-Timofei, Sorin Avram and Yvan Vander Heyden
Affiliation:
Keywords: Conformational analysis, Benzoxazinone derivative, Biologically active conformation, Human neutrophil elastase inhibitor, Molecular docking, serine proteinase, chymotrypsin family, anti-inflammatory compounds, 2-pyridin-3-yl-benzo[d][1, 3]oxazin-4-one derivatives, MOPAC software
Abstract: Neutrophil elastase, a serine proteinase from the chymotrypsin family, has been the object of comprehensive experimental and theoretical studies to develop efficient human neutrophil elastase inhibitors. The serine protease has been linked to the pathology of a variety of inflammatory diseases, making it an attractive target for the development of anti-inflammatory compounds.
In this work, we have built a common binding model of the 2-pyridin-3-yl-benzo[d][1,3]oxazin-4-one derivatives into the human neutrophil elastase binding site. This was accomplished through a comparative conformational analysis (using OMEGA, HYPERCHEM, and MOPAC software) of 2-pyridin-3-yl-benzo[d][1,3]oxazin-4-one inhibitors followed by rigid and flexible molecular docking (by the FRED and GLIDE programs) into the target protein. We conclude that OMEGA software generates the most representative conformers to model the protein-ligand interactions.Export Options
About this article
Cite this article as:
Goodarzi Mohammad, Bora Alina, Borota Ana, Funar-Timofei Simona, Avram Sorin and Vander Heyden Yvan, Modeling of 2-Pyridin-3-yl-Benzo[d][1,3]Oxazin-4-one Derivatives by Several Conformational Searching Tools and Molecular Docking, Current Pharmaceutical Design 2013; 19 (12) . https://dx.doi.org/10.2174/1381612811319120007
DOI https://dx.doi.org/10.2174/1381612811319120007 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Increased Neuronal Injury in Transgenic Mice with Neuronal Overexpression of Human Cyclooxygenase-2 is reversed by Hypothermia and Rofecoxib Treatment
Current Neurovascular Research MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Favorable Effects of Astaxanthin on Brain Damage due to Ischemia- Reperfusion Injury
Combinatorial Chemistry & High Throughput Screening Compounds that Combine Aldose Reductase Inhibitory Activity and Ability to Prevent the Glycation (Glucation and/or Fructation) of Proteins as Putative Pharmacotherapeutic Agents
Drug Design Reviews - Online (Discontinued) The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Angiogenesis and Blood-Brain Barrier Permeability in Vascular Remodeling after Stroke
Current Neuropharmacology Mild Systemic Inflammation has a Neuroprotective Effect After Stroke in Rats
Current Neurovascular Research Human Urotensin II and Metabolic Syndrome
Vascular Disease Prevention (Discontinued) Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology Pharmacological Management of No Reflow During Percutaneous Coronary Intervention
Current Vascular Pharmacology Sida cordifolia, a Traditional Herb in Modern Perspective – A Review
Current Traditional Medicine Exploring the Anti-Neuroinflammatory Potential of Steroid and Terpenoid-Derived Phytochemicals to Combat Alzheimer's Disease
Current Pharmaceutical Design Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia
Current Signal Transduction Therapy Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Intranasal Fluorescent Nanocrystals for Longitudinal <i>In Vivo</i> Evaluation of Cerebral Microlesions
Pharmaceutical Nanotechnology Liposomes: Targeted and Controlled Delivery System
Drug Delivery Letters Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design